Scientists have identified a protein that, when disabled in mice, appears to make them resistant to obesity, and new research suggests similar effects in human cells. The findings could lay the groundwork for a new class of weight-loss therapies that work very differently from today’s GLP-1 drugs.
The protein, called MTCH2 and nicknamed Mitch, was previously shown to protect mice against diet-induced obesity when its production was blocked in muscle tissue. Those animals also displayed greater stamina and endurance, prompting researchers to investigate whether the same mechanism might also apply to humans.
From mouse muscles to human cells
A team led by the Weizmann Institute of Science in Israel used gene-editing techniques to knock out MTCH2 in cultured human cells. They then monitored more than 100 metabolic compounds over time to map how the loss of the protein altered energy metabolism within the cells.
According to study co-author Sabita Chourasia, deleting MTCH2 triggered a clear increase in cellular respiration, the oxygen-dependent process that converts nutrients such as carbohydrates and fats into energy. This pattern mirrors earlier mouse experiments, in which enhanced cellular respiration was associated with improved muscular endurance.
The new study also clarifies the function of Mitch. The protein appears to limit the ability of mitochondria—the cell’s energy-producing organelles—to fuse into more efficient networks. When MTCH2 is absent, mitochondrial fusion occurs more readily, allowing cells to burn available fuel more efficiently to meet increased energy demands.
Fat burned faster and stored less
In MTCH2-deficient cells, carbohydrates, fats, and amino acids were all consumed more rapidly, creating what the researchers describe as a hypermetabolic state. The cells increasingly relied on fat as an energy source, even breaking down the fatty components of their own cellular membranes.
Co-author Atan Gross reported that membrane fat levels declined markedly after MTCH2 was removed, while the concentration of fatty molecules used directly for energy production increased. This finding suggests that MTCH2 plays an important role in determining whether fats are stored as structural components or broken down to fuel cellular activity.
The researchers also found that the loss of MTCH2 disrupted adipocyte differentiation, the process by which precursor cells mature into fat-storing adipocytes. Without Mitch, this energy-demanding process stalled, and the genes required for fat-cell development became less active, resulting in reduced formation of new fat cells.
Promise and risks for future therapies
Taken together, these findings suggest that MTCH2 regulates both the rate at which fat is burned and the formation of new fat tissue. This dual function makes the protein an attractive target for future anti-obesity therapies, particularly as researchers seek alternatives to GLP-1 medications such as Ozempic and Wegovy.
However, the researchers caution that forcing cells into a chronically energy-deficient state may also carry risks. Sustained hypermetabolism could place excessive stress on tissues and organs, potentially causing damage if energy demand consistently exceeds energy supply.
In their paper, the authors conclude that knocking out MTCH2 produces a profound shift in cellular energy metabolism by activating multiple pathways that support increased energy utilization. They argue that the protein serves as a central regulator of metabolic balance but emphasize that extensive studies in animals and, ultimately, in humans will be necessary before any therapy targeting MTCH2 can be considered safe.
As obesity rates continue to rise worldwide, this discovery introduces a promising new mechanism for metabolic research. If scientists can successfully fine-tune MTCH2 activity without triggering harmful side effects, future treatments may help patients burn fat more efficiently while avoiding some of the muscle and bone loss associated with existing weight-loss medications.
